Anika Therapeutics, Inc.
ANIK
$15.05
$0.020.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.67% | -27.56% | -25.35% | -21.64% | -22.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.67% | -27.56% | -25.35% | -21.64% | -22.69% |
| Cost of Revenue | 113.70% | -4.08% | -38.39% | -36.54% | -36.91% |
| Gross Profit | -13.98% | -41.61% | -17.65% | -12.55% | -13.94% |
| SG&A Expenses | 28.11% | -49.41% | -41.51% | -35.79% | -29.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.25% | -33.55% | -39.93% | -34.94% | -30.87% |
| Operating Income | -2,263.69% | 66.99% | 132.79% | 118.07% | 109.83% |
| Income Before Tax | -1,091.38% | 78.79% | 154.12% | 139.55% | 116.84% |
| Income Tax Expenses | -13.30% | 410.87% | 303.20% | 273.83% | 269.67% |
| Earnings from Continuing Operations | -976.07% | 25.57% | 122.77% | 110.76% | 76.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.79% | -296.83% | -234.53% | -244.90% | -456.34% |
| EBIT | -2,263.69% | 66.99% | 132.79% | 118.07% | 109.83% |
| EBITDA | -264.14% | 101.60% | 275.04% | 260.34% | 1,022.35% |
| EPS Basic | 31.95% | -295.72% | -234.29% | -244.25% | -453.48% |
| Normalized Basic EPS | -919.15% | 73.25% | 145.43% | 129.03% | 124.91% |
| EPS Diluted | 31.85% | -293.66% | -231.52% | -241.06% | -447.48% |
| Normalized Diluted EPS | -919.21% | 73.25% | 145.43% | 129.03% | 124.91% |
| Average Basic Shares Outstanding | 0.43% | 0.59% | 0.42% | 0.39% | 0.63% |
| Average Diluted Shares Outstanding | 0.51% | 0.59% | 0.42% | 0.39% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
